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Abstract: Restaging local recurrence after high-intensity focused ultra-
sound (HIFU) is based on multiparametric MRI (mpMRI). However,
postinterventional changes of the tissue, such as edema or hemorrhage,
are limiting tumor detection on mpMRI. We present a case of a rising prostate-
specific antigen values, negative mpMRI, and a Gleason score of 4+4 on
template biopsy after HIFU. On 18F-choline PET/MR, high focal uptake
was detected at the location of positive biopsy. Re-HIFU based on the fused
18F-choline PET/MR images was performed, followed by a recurrence-free
period of 11 months. Thus, 18F-choline PET/MR could improve guiding
retreatment in patients with recurrence after HIFU.
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FIGURE 1. Multiparametric MRI (mpMRI) performed 6 months after high-intensity focused ultrasound (HIFU) due to a rising
prostate-specific antigen (PSA) from nadir 1.6 ng/mL to 2.5 ng/mL and a positive template biopsy (Gleason score 4 + 4). A,
Axial T2-weighted image shows posttherapeutic changes in the right lobe of the prostate gland without any clear delineation of
a focal lesion. B, Axial high b-value diffusion-weighted imaging (DWI) (b = 1400) showed no focal diffusion restriction,
and (C) the corresponding contrast enhanced scan showed no increased focal enhancement.
FIGURE 2. Onemonth later, an 18F-choline PET/MRwas performed to reassess the prostate. Axial T2-weighted image (A) reveals
a hypointense lesionwithin the right anterior lobe of the prostate, whereas diffusion images show a hypointense signal on both
DWI image (B) and apparent diffusion coefficientmap (C). Coronal 18F-cholineMIP image shows a clear focal uptake in the right
peripheral lobe (D). Fused axial 18F-choline PET with T2 MR confirms the focal choline-avid lesion within the right anterior
prostate gland (SUVmax 4.5) (E), highly suggestive ofmalignancy,with good correlation to the cancer positive cores (red arrow) on
the transperineal template biopsy that revealed a Gleason score 4 + 4 (F). A re-HIFU was performed based on PET/MR findings,
with falling PSA levels to 0.2 ng/mL 4 months later. Five-year disease-free survival rates after HIFU ablation of clinically localized
prostate cancer range between 66% and 78%.1,2 In patients with disease recurrence, tumor localization could facilitate further
targeted treatment. To achieve this, mpMRI including perfusion images was suggested to increase the detection of significant
tumor compared with unguided transrectal biopsy after HIFU.3 Some authors even suggest that template biopsy is not needed if
a high-quality mpMRI is negative.4 In our experience, however, significant tumor found on template biopsy often lacks a clear
correlate onmpMRI, including dynamic contrast-enhanced and DWI images. 18F-choline PET is known to be positive in prostate
cancerwith a good sensitivity and impaired specificity due to intense uptake in benign prostate hyperplasia.5,6 However, it has been
shown that the combination of 18F-choline PET with MRI in hybrid systems can improve the specificity because benign prostate
hyperplasia can be characterizedwithMRI.7,8 This is the first report showing that 18F-choline PET/MR could localize recurrence after
HIFUwith a good correlation to template biopsy. Furthermore, the tumor delineation allows planning a re-HIFU based on the PET
uptake, with a very promising decrease in PSA of more than 90% after re-HIFU.
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